Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1
A biomarker is a gene, protein, or molecule produced by the body or tumor in a person with cancer that tells a doctor something about the cancer cells. MBC...
Read MoreOncolytic Viruses: Using Viruses to Kill Cancer Cells
Oncolytic viruses are being studied in clinical trials as a new way of treating cancer. This type of treatment uses viruses to kill cancer cells, though the...
Read MoreLobular Breast Cancer Metastasis: Highlighting the Researchers
In our five-part series, we are highlighting researchers and physicians that study and treat breast cancer that has spread to common sites: brain, bones, liver,...
Read MoreWhat is Measurable Disease?
In clinical trials, a common eligibility requirement is measurable disease. This is because researchers are often required to measure the size of tumors to...
Read MoreCURE®’s Educated Patient® Metastatic Breast Cancer Summit
On June 11, 2022, CURE® held a virtual Educated Patient® Metastatic Breast Cancer Summit. Click on the link below to view videos, transcripts, and other coverage...
Read MoreNew Announcement: Introduction to MBC Clinical Trials Video
We are excited to announce our brand new MBC clinical trials introduction video. The 2:58 video is a beautiful and informational introduction to MBC trials...
Read MoreWhat is it Like to Participate in a Clinical Trial?
Progress in treating metastatic breast cancer is possible because of people who choose to participate in clinical trials. Click the links to learn from the...
Read MoreFDA Approves Enhertu® for HER2-Low MBC
On August 5, 2022, the FDA approved trastuzumab deruxtecan (Enhertu®) for the treatment of people with HER2-low MBC who have received chemotherapy. This new...
Read MoreWhy Knowing Your HER2 Status is Important
Your cancer may be HER2-negative, HER2-positive, or HER2-low depending on the levels of the HER2 protein found on the surface of your cancer cells. Understanding...
Read MoreSEARCH OUR SITE
for past articles or specific information.